In 2019, we published a piece exploring the correlation between increased access to medical cannabis and a decrease in opioid use. Two years is a long time when it comes to medical cannabis research, and since the last post there have been significant and timely developments in the field of cannabis research as it relates …
Cannabis, Opioids and Pain: An Update on the Research Read More »
In the RYAH Data ecosystem, approximately 42 percent of patients prefer sativa and sativa-dominant cultivars, while 44.2 percent prefer indica and indica-dominant strains. Under a scientific lens, do these two foundational cannabis categories still make sense? The cannabis industry may be built around the idea of two phytochemically and genetically distinct varieties, but these …
Sativa versus Indica: Moving From Cultivar to Chemovar Read More »
Women\’s health, a topic traditionally excluded from scientific research, is slowly getting more recognition. Menopause is one such condition getting renewed attention, including through the lens of medical cannabis. Menopause, characterized by the end of menstruation, with symptoms ranging from hot flashes, chills, night sweats, sleep problems, mood changes, and slowed metabolism, is a …
Past and Present: Cannabis for the Treatment of Menopause Read More »
Between January 1, 2018, and November 1, 2020, there have been more than 9,000 sessions of patients consuming medical cannabis for obsessive-compulsive disorder (OCD) within the RYAH Data ecosystem. This evidence adds to the chorus of anecdotal reports, case studies, and several hypothetical scientific reviews on the subject. Could medical cannabis improve functional impairment caused …
Medical Cannabis for OCD? Hints from Case Studies, Comorbities and the ECS Read More »
For decades, the misunderstood relationship between cannabis and schizophrenia has sowed fear among regulators, healthcare providers, and law enforcement. Opposition to legalization has often come wrapped in alarm that rising cannabis consumption will trigger rising rates of psychosis and schizophrenia. [/caption] Yet, more than 80 years after the film “Reefer Madness” incited this panic about cannabis, …
The world is in the midst of an unprecedented global pandemic. Governments, research centers, and international health organizations are throwing everything they have at finding a solution to the newly discovered coronavirus disease (COVID-19). With 30 million total cases and counting, there is a pressing need for a vaccine and an effective treatment. Two such …
What\’s the Hype? Cannabinoid Therapy for COVID-19 Read More »
First it won over millennials. Then came the Baby Boomers. Now medical cannabis is piquing the interest of patients over the age of 65. Despite initial hesitations during the first wave of legalization, seniors are slowly coming around to the value of medical cannabis. This rapid shift is thanks to the unique combination of …
Curiosity About Medical Cannabis: Special Considerations for Older patients Read More »
The UK may have legalized medical cannabis in 2018, but that doesn\’t mean patients can access it. According to a recent report in The Guardian, just two patients are receiving medical cannabis through the National Healthcare Service (NHS). Both received special emergency interim licenses from the Home Office. Outside the public system, there are perhaps …
UK Public Awareness of Medical Cannabis is Positive, But the System is Broken Read More »
The endocannabinoid theory of disease began with the discovery of the endocannabinoid system. Unlike the central nervous system, the respiratory system, and other essential systems which have been investigated for centuries, researchers only stumbled onto the existence of the endocannabinoid system less than 30 years ago. As one of the newest physiological revelations, it\’s …
The Endocannabinoid Theory: Applications for Cannabinoid Therapy Read More »
The European cannabis market is a much different beast than what has evolved across the pond in North America. If North America is about wild market predictions, high-risk investments, and murky regulation, Europe is the exact opposite. The European markets are slow to launch, measured in their approach, and highly regulated. Germany, which RYAH …
An Update on the German Model: A Study Case for the Rest of the EU Read More »
We never spam your inbox. You will always get the most accurate news and updates, signup now!
